Cano-Parra J, Diaz-Llopis M, Maldonado M J, Vila E, Menezo J L
Department of Ophthalmology, La Fe University Hospital, Valencia, Spain.
Br J Ophthalmol. 1995 May;79(5):439-41. doi: 10.1136/bjo.79.5.439.
A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted.
A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months).
Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group.
Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.
开展一项关于术中使用丝裂霉素C作为原发性翼状胬肉辅助治疗的前瞻性、随机、双盲、安慰剂对照研究。
对54例原发性翼状胬肉患者的66只眼进行手术切除,部分患者术中单次应用丝裂霉素C(0.1mg/ml,持续5分钟),以评估这种辅助治疗的疗效和毒性。平均随访时间为14.1个月(范围12 - 23个月)。
单纯手术切除的36只眼中,14只(38.8%)复发,而手术切除联合术中应用丝裂霉素C治疗的30只眼中仅有1只(3.33%)复发(p = 0.0006)。丝裂霉素C治疗组未观察到严重眼部并发症和全身毒性。
术中使用丝裂霉素C似乎是原发性翼状胬肉一种有效且安全的辅助治疗方法。